The tzield market research report is one of a series of new reports that provides tzield market statistics, including tzield industry global market size, regional shares, competitors with a tzield market share, detailed tzield market segments, market trends and opportunities, and any further data you may need to thrive in the tzield industry. This tzield market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The growth in the forecast period can be attributed to the growing prevalence of autoimmune diseases, growing research and development activities, increased automation of laboratories, and rising prevalence of type 1 diabetes. Major trends in the forecast period include advancements in biotechnology, innovations in cell culture systems, emerging technologies, personalized medicine, and combination therapies.
The growing prevalence of type 1 diabetes is expected to drive the expansion of the Tzield market. Type 1 diabetes is a chronic autoimmune disease in which the body’s immune system attacks and destroys the insulin-producing beta cells in the pancreas. This rise in prevalence is partly due to advances in diagnostic technology, which allows for more cases to be identified, as well as environmental factors such as changes in diet and reduced exposure to infections, which can influence immune system development. Tzield addresses this trend by delaying the onset of Stage 3 type 1 diabetes, reducing the need for insulin and the associated risks, while offering a new option to manage the disease’s progression. For example, in 2024, Breakthrough T1D, a U.S.-based organization dedicated to research and advocacy for Type 1 Diabetes, estimated that approximately 215,000 children and adolescents under 20, and 353,000 adults over 20 worldwide were diagnosed with type 1 diabetes. In the United States, this included about 21,000 children and adolescents under 20 and 42,000 adults over 20. As the number of type 1 diabetes cases rises, so does the demand for Tzield.
A major trend in the Tzield market is the approval of the drug by regulatory agencies to delay the onset of Stage 3 type 1 diabetes in both adults and pediatric patients aged 8 and older who have Stage 2 type 1 diabetes. The approval process involves regulatory bodies evaluating and authorizing new drugs for use, ensuring their safety, effectiveness, and quality based on clinical trial data. In November 2022, Provention Bio Inc., a U.S.-based biopharmaceutical company, received approval from the U.S. Food and Drug Administration (FDA) for Tzield (teplizumab-mzwv). This drug is specifically indicated to delay the progression to Stage 3 type 1 diabetes in patients aged 8 years and older with Stage 2 disease. Administered through a 14-day intravenous infusion, Tzield works by modulating the immune response to protect insulin-producing beta cells from autoimmune destruction. Clinical trials showed that Tzield significantly reduced the risk of progression to Stage 3, with treated patients experiencing a longer median time to diagnosis compared to those on a placebo.
In April 2023, Sanofi S.A., a France-based pharmaceutical company, acquired Provention Bio, aiming to strengthen its innovative diabetes therapy portfolio. This acquisition allows Sanofi to expand its offerings with Tzield, a first-in-class treatment designed to delay the onset of Stage 3 type 1 diabetes. The move aligns with Sanofi’s broader strategy to address unmet needs in immune-mediated diseases and improve global patient access to new therapies. Provention Bio, which developed and distributed Tzield, is now part of Sanofi’s growing commitment to diabetes care.
The countries covered in the tzield market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Tzield (teplizumab-mzwv) is a monoclonal antibody used to delay the onset of stage 3 type 1 diabetes in individuals aged 8 years and older who are at risk. It works by modulating the immune system, specifically targeting and deactivating autoreactive T lymphocytes that attack the pancreatic beta cells responsible for insulin production.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The primary clinical indications for tzield include Type 1 diabetes and Type 2 diabetes. Type 1 diabetes is a chronic condition where the pancreas produces little to no insulin, typically diagnosed in childhood or adolescence. Tzield is available in various formulations, such as intravenous infusion and single-dose vials, and is distributed through hospitals, clinics, retail pharmacies, and specialty pharmacies. It serves a wide range of end users, including both adults and pediatric patients.
The tzield market consists of sales of immunotherapy drugs, monoclonal antibodies (mAbs), and disease-modifying therapies. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The growth in the forecast period can be attributed to the growing prevalence of autoimmune diseases, growing research and development activities, increased automation of laboratories, and rising prevalence of type 1 diabetes. Major trends in the forecast period include advancements in biotechnology, innovations in cell culture systems, emerging technologies, personalized medicine, and combination therapies.
The growing prevalence of type 1 diabetes is expected to drive the expansion of the Tzield market. Type 1 diabetes is a chronic autoimmune disease in which the body’s immune system attacks and destroys the insulin-producing beta cells in the pancreas. This rise in prevalence is partly due to advances in diagnostic technology, which allows for more cases to be identified, as well as environmental factors such as changes in diet and reduced exposure to infections, which can influence immune system development. Tzield addresses this trend by delaying the onset of Stage 3 type 1 diabetes, reducing the need for insulin and the associated risks, while offering a new option to manage the disease’s progression. For example, in 2024, Breakthrough T1D, a U.S.-based organization dedicated to research and advocacy for Type 1 Diabetes, estimated that approximately 215,000 children and adolescents under 20, and 353,000 adults over 20 worldwide were diagnosed with type 1 diabetes. In the United States, this included about 21,000 children and adolescents under 20 and 42,000 adults over 20. As the number of type 1 diabetes cases rises, so does the demand for Tzield.
A major trend in the Tzield market is the approval of the drug by regulatory agencies to delay the onset of Stage 3 type 1 diabetes in both adults and pediatric patients aged 8 and older who have Stage 2 type 1 diabetes. The approval process involves regulatory bodies evaluating and authorizing new drugs for use, ensuring their safety, effectiveness, and quality based on clinical trial data. In November 2022, Provention Bio Inc., a U.S.-based biopharmaceutical company, received approval from the U.S. Food and Drug Administration (FDA) for Tzield (teplizumab-mzwv). This drug is specifically indicated to delay the progression to Stage 3 type 1 diabetes in patients aged 8 years and older with Stage 2 disease. Administered through a 14-day intravenous infusion, Tzield works by modulating the immune response to protect insulin-producing beta cells from autoimmune destruction. Clinical trials showed that Tzield significantly reduced the risk of progression to Stage 3, with treated patients experiencing a longer median time to diagnosis compared to those on a placebo.
In April 2023, Sanofi S.A., a France-based pharmaceutical company, acquired Provention Bio, aiming to strengthen its innovative diabetes therapy portfolio. This acquisition allows Sanofi to expand its offerings with Tzield, a first-in-class treatment designed to delay the onset of Stage 3 type 1 diabetes. The move aligns with Sanofi’s broader strategy to address unmet needs in immune-mediated diseases and improve global patient access to new therapies. Provention Bio, which developed and distributed Tzield, is now part of Sanofi’s growing commitment to diabetes care.
The key company operating in the tzield market is Sanofi S.A
North America was the largest region in the tzield market in 2024. The regions covered in tzield report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.The countries covered in the tzield market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Tzield (teplizumab-mzwv) is a monoclonal antibody used to delay the onset of stage 3 type 1 diabetes in individuals aged 8 years and older who are at risk. It works by modulating the immune system, specifically targeting and deactivating autoreactive T lymphocytes that attack the pancreatic beta cells responsible for insulin production.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The primary clinical indications for tzield include Type 1 diabetes and Type 2 diabetes. Type 1 diabetes is a chronic condition where the pancreas produces little to no insulin, typically diagnosed in childhood or adolescence. Tzield is available in various formulations, such as intravenous infusion and single-dose vials, and is distributed through hospitals, clinics, retail pharmacies, and specialty pharmacies. It serves a wide range of end users, including both adults and pediatric patients.
The tzield market consists of sales of immunotherapy drugs, monoclonal antibodies (mAbs), and disease-modifying therapies. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Tzield Market Characteristics4. Tzield Market Trends And Strategies5. Tzield Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market7. Global Tzield Pricing Analysis & Forecasts30. Global Tzield Market Competitive Benchmarking And Dashboard31. Key Mergers And Acquisitions In The Tzield Market32. Recent Developments In The Tzield Market
3. Tzield Market Biologic Drug Characteristics
6. Global Tzield Growth Analysis And Strategic Analysis Framework
8. Tzield Market Segmentation
9. Global Tzield Epidemiology Of Clinical Indications
10. Tzield Market Regional And Country Analysis
11. Asia-Pacific Tzield Market
12. China Tzield Market
13. India Tzield Market
14. Japan Tzield Market
15. Australia Tzield Market
16. South Korea Tzield Market
17. Western Europe Tzield Market
18. UK Tzield Market
19. Germany Tzield Market
20. France Tzield Market
21. Eastern Europe Tzield Market
22. North America Tzield Market
23. USA Tzield Market
24. Canada Tzield Market
25. South America Tzield Market
26. Middle East Tzield Market
27. Africa Tzield Market
28. Tzield Market Competitive Landscape And Company Profiles
29. Global Tzield Market Pipeline Analysis
33. Tzield Market High Potential Countries, Segments and Strategies
34. Appendix
Executive Summary
Tzield Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on tzield market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for tzield ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The tzield market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Clinical Indication: Type 1 Diabetes; Type 2 Diabetes2) By Formulation: Intravenous Infusion; Single-Dose Vials
3) By Distribution Channel: Hospital And Clinics; Retail And Specialty Pharmacies
4) By End User: Adult; Pediatric
Key Companies Profiled: Sanofi S.A
Countries: Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- Sanofi S.A
